WikiPsiquiatria - Posts previos
Mostrando entradas con la etiqueta Effects. Mostrar todas las entradas
Mostrando entradas con la etiqueta Effects. Mostrar todas las entradas

Effects of stress can be inherited, and here's how

ScienceDaily (June 24, 2011) — None of us are strangers to stress of various kinds. It turns out the effects of all those stresses can change the fate of future generation, influencing our very DNA without any change to the underlying sequence of As, Gs, Ts and Cs. Now, researchers reporting in the June 24 issue of Cell, a Cell Press publication, have new evidence that helps to explain just how these epigenetic changes really happen.

"There has been a big discussion about whether the stress effect can be transmitted to the next generation without DNA sequence change," said Shunsuke Ishii of RIKEN Tsukuba Institute. "Many people were doubtful about such phenomena because the mechanism was unknown. Our finding has now demonstrated that such phenomena really can occur."

Our genes encode proteins, but whether and how those genetic instructions are ultimately read and expressed depends on how those genes are chemically modified and "packaged" into a more complex structure known as chromatin. Some portions of the genome are more tightly wound into what's known as heterochromatin. Heterochromatin is maintained from one generation to the next and typically doesn't contain active genes, Ishii explains.

Over 20 years ago, Ishii and his colleagues discovered a gene in yeast (called activation transcription factor-2 or ATF-2 for short)that is required for those tightly packed, heterochromatin structures to form. ATF-2 is altered by stress-activated protein kinases in response to environmental stress, inflammatory cytokines, and reactive oxygen species (ROS). But it wasn't entirely clear what this might mean for other organisms.

Ishii and his colleagues now confirm that ATF-2 is required for heterochromatin assembly in multicellular organisms. When fruitflies are exposed to stressful conditions, the ATF-2 is modified and disrupts heterochromatin, releasing genes from their usual silenced state. Importantly, these changes in genomic structure are passed on from one generation to the next.

The researchers expect that this finding in flies has relevance for humans, noting that we also carry the ATF-2 gene. Those epigenetic changes may influence basic cellular functions as well as metabolism, behavior and disease. In particular, Ishii suggests that epigenetic causes may play a role in "lifestyle diseases," including heart disease and diabetes, and in psychological diseases, such as schizophrenia.

If that's true, there may be some hope. Drugs targeting the enzymes that modify ATF-2 in response to stress have already been developed.

According to Ishii, the take-home message is this: "I hope that people understand that various stresses can change gene expression without DNA sequence change." He says the youngest among us -- developing embryos and infants -- may be especially sensitive to that kind of stress-induced epigenetic change and "we should be more careful about stresses on them."

Story Source:

The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by Cell Press, via EurekAlert!, a service of AAAS.

Journal Reference:

Ki-Hyeon Seong, Dong Li, Hideyuki Shimizu, Ryoichi Nakamura, Shunsuke Ishii. Inheritance of Stress-Induced, ATF-2-Dependent Epigenetic Change. Cell, 2011; 145 (7): 1049-1061 DOI: 10.1016/j.cell.2011.05.029

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.



View the original article here

Parkinson's Patients Get No Benefit From Antidepressants Sertraline Or Mirtazapine, But Have More Side Effects


Editor's Choice
Academic Journal
Main Category: Parkinson's Disease
Also Included In: Depression;  Psychology / Psychiatry
Article Date: 19 Jul 2011 - 15:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions  
3 starsnot yet rated
Two antidepressants prescribed often for individuals with Parkinson's disease - sertraline or mirtazapine - were found to have no benefits for such patients. In fact, they also experienced unpleasant side effects., according to the results of the HTA-SADD trial published in The Lancet. The article was written by Professor Sube Banerjee and team, Institute of Psychiatry, King's College London, UK.

The trial involved 325 patients from nine different centers in England. They all had either possible Alzheimer's disease, depression which had lasted at least 4 weeks, or a dementia-related depression above a certain score. Any patient who was a suicide risk, contraindicated for the drugs, was already on antidepressants, or was at the time already taking part in another trial, was ineligible for this study.

They were randomly selected into one of three groups: Sertraline group - 150mg per day - 107 patientsMirtazapine group - 45 mg per day - 107 patientsControl group - placebo - 111 patientsThe researchers were focusing (primary outcome) on how much depression might be reduced after 13 weeks of treatment. They all also received standard care.

At 13 weeks there were no differences in the depression scores among the three groups, not even at 39 weeks.

26% of those on the placebo group experienced adverse reactions, compared to 43% in the sertraline group and 41% in the mirtazapine group. By week 39 five participants had died in each group.

The researchers concluded:

"The two classes of antidepressants most likely to be prescribed for depression in Alzheimer's disease are no more effective than placebo. In our study, there were more adverse reactions in individuals treated with antidepressants than there were with placebo. Clinicians and investigators need to reframe the way they think about the treatment of people with Alzheimer's disease who are depressed, and reconsider routine prescription of antidepressants."

Dr Henry Brodaty, Brain and Ageing Research Program and Primary Dementia Collaborative Research Centre, University of New South Wales, Sydney, Australia, concluded in a Comment in the same journal:

"The HTA-SADD trial has underscored the need for clinicians to think about creative alternatives to drug treatment for management of depression in people with dementia, and to use evidence-based techniques and partnerships with family carers."

"Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial"
Prof Sube Banerjee MD, Jennifer Hellier MSc, Michael Dewey PhD, Renee Romeo PhD, Clive Ballard MD, Robert Baldwin MD, Peter Bentham MRCPsych, Chris Fox MD, Clive Holmes PhD, Cornelius Katona MD, Martin Knapp PhD, Claire Lawton FRCPsych, James Lindesay DM, Gill Livingston MD, Niall McCrae PhD, Esme Moniz-Cook PhD, Joanna Murray MA, Shirley Nurock MSc, Martin Orrell PhD, John O'Brien DM, Michaela Poppe PhD, Alan Thomas PhD, Rebecca Walwyn PhD, Kenneth Wilson MD, Alistair Burns MD

The Lancet, Early Online Publication, 18 July 2011 doi:10.1016/S0140-6736(11)60830-1

Written by Christian Nordqvist
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Please rate this article:
(Hover over the stars
then click to rate) Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.




View the original article here

Medscape Psychiatry

Scientific American - Mind & Brain

Nature Reviews Neuroscience - Issue - nature.com science feeds

Nature Reviews Neuroscience - AOP - nature.com science feeds

Nature Neuroscience - Issue - nature.com science feeds

Nature Neuroscience - AOP - nature.com science feeds

Translational Psychiatry

Neuropsychopharmacology - AOP - nature.com science feeds

Neuropsychopharmacology - Issue - nature.com science feeds